Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;46(3):1138-1145.
doi: 10.1177/0300060517735231. Epub 2017 Dec 6.

Current management of refractory ascites in patients with cirrhosis

Affiliations
Review

Current management of refractory ascites in patients with cirrhosis

Ruihong Zhao et al. J Int Med Res. 2018 Mar.

Abstract

Liver cirrhosis is a health problem worldwide, and ascites is its principal symptom. Refractory ascites is intractable and occurs in 5%-10% of all patients with ascites due to cirrhosis. Refractory ascites leads to a poor quality of life and high mortality rate. Ascites develops as a result of portal hypertension, which leads to water-sodium retention and renal failure. Various therapeutic measures can be used for refractory ascites, including large-volume paracentesis, transjugular intrahepatic portosystemic shunt, vasoconstrictive drugs, and an automated low-flow ascites pump system. However, ascites generally can be resolved only by liver transplantation. Because not all patients can undergo liver transplantation, traditional approaches are still used to treat refractory ascites. The choice of treatment modality for refractory ascites depends, among other factors, on the condition of the patient.

Keywords: Cirrhosis; automated low-flow ascites pump; liver; paracentesis; refractory ascites; transjugular intrahepatic portosystemic shunt.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Tandon P andGarcia-Tsao G.. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26–42. - PubMed
    1. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122–128. - PubMed
    1. Bories P, Garcia CD, Michel H, et al. The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J Hepatol 1986; 3: 212–218. - PubMed
    1. Arroyo V andColmenero J.. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38(Suppl 1): S69–S89 - PubMed
    1. Reynolds TB. Ascites. Clin Liver Dis 2000; 4: 151–168. - PubMed

MeSH terms

Substances